Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor cell lysis via viral replication leverages engineered or naturally selective viruses that exploit vulnerabilities specific to malignant tissues. By directly lysing tumor cells through robust intracellular replication—and simultaneously priming systemic anti-tumor immunity—this strategy represents a promising avenue for targeted oncologic therapy with expanding applications across diverse malignancies.
Selective infection/replication -> direct lysis -> release & spread; Stimulation of anti-tumor immunity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Cell Lysis via Viral Replication (Oncolysis).